Institut Curie - Site Saint-Cloud

The site emphasizes cutting‑edge diagnostic imaging and molecular monitoring to guide cancer treatment decisions.

• ctDNA‑based surveillance for early detection of relapse
• PSMA PET/CT imaging for oligometastatic prostate cancer
• Advanced radiotherapy planning combined with immunotherapy

Institut Curie – Saint‑Cloud leverages these technologies to improve patient stratification across multiple tumor types.

Research targets malignancies of the gastrointestinal tract, aiming to test novel systemic therapies and improve outcomes.

• Colorectal cancer trials evaluating targeted agents
• Hepatocellular carcinoma studies with combination regimens
• Esophageal carcinoma combined with definitive chemoradiotherapy

The program integrates precision medicine approaches to address the unique biology of digestive system cancers.

A broad portfolio focuses on blood‑derived cancers, including acute leukemias and diverse lymphoma subtypes.

• Acute myeloid leukemia (AML) investigational therapies
• Chronic lymphocytic leukemia (CLL) and related disorders
• Follicular, marginal zone, and mantle‑cell lymphomas
• Diffuse large B‑cell lymphoma (DLBCL) treatment optimization
• Myelodysplastic syndrome (MDS) and myeloproliferative overlap studies

These efforts aim to enhance response rates and durability of remission for patients with hematologic malignancies.

Clinical investigations address prostate cancer at various stages, seeking to delay progression and improve survival.

• Oligometastatic prostate cancer evaluated with PSMA‑targeted radioligand therapy
• Biochemically recurrent disease after primary treatment
• Advanced prostate cancer combined with androgen‑deprivation therapy

The site’s work reflects a commitment to personalized strategies for men at risk of disease recurrence.

A major focus is on solid tumors, especially breast, ovarian, and endometrial cancers, testing innovative combinations and endocrine approaches.

• Advanced or metastatic breast cancer, including HER2‑positive and triple‑negative subtypes
• ER‑positive, HER2‑negative disease evaluated with novel endocrine agents
• Ovarian, fallopian tube, and primary peritoneal carcinoma studies
• Endometrial cancer trials exploring maintenance therapies
• Metastatic non‑small cell lung cancer (mNSCLC) comparative immunotherapy research

These trials aim to expand therapeutic options and extend disease‑free intervals for patients with diverse neoplasms.

Investigations seek to refine biomarkers and early‑detection methods that signal disease activity or treatment response.

• ctDNA monitoring to predict early death risk
• Early detection of triple‑negative breast cancer relapse
• Biomarker‑driven assessment of treatment efficacy

By focusing on these indicators, Institut Curie – Saint‑Cloud aims to intervene sooner and tailor therapies more precisely.

The center incorporates health‑care environment considerations, ensuring trial safety, patient wellbeing, and broader public health impact.

• Safety and tolerability assessments across novel agents
• Evaluation of survivorship care models
• Integration of patient‑reported outcomes in trial design

This holistic approach supports the delivery of high‑quality oncology care within a responsible public‑health framework.